JP5346820B2 - Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 - Google Patents

Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 Download PDF

Info

Publication number
JP5346820B2
JP5346820B2 JP2009553239A JP2009553239A JP5346820B2 JP 5346820 B2 JP5346820 B2 JP 5346820B2 JP 2009553239 A JP2009553239 A JP 2009553239A JP 2009553239 A JP2009553239 A JP 2009553239A JP 5346820 B2 JP5346820 B2 JP 5346820B2
Authority
JP
Japan
Prior art keywords
antibody
seq
subtype
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009553239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521147A (ja
JP2010521147A5 (enExample
Inventor
アントニオ・ランツァヴェッキア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs LLC
Original Assignee
Humabs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs LLC filed Critical Humabs LLC
Publication of JP2010521147A publication Critical patent/JP2010521147A/ja
Publication of JP2010521147A5 publication Critical patent/JP2010521147A5/ja
Application granted granted Critical
Publication of JP5346820B2 publication Critical patent/JP5346820B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C07K16/108—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009553239A 2007-03-13 2008-03-13 Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 Expired - Fee Related JP5346820B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89461207P 2007-03-13 2007-03-13
US60/894,612 2007-03-13
PCT/IB2008/001527 WO2008110937A2 (en) 2007-03-13 2008-03-13 Antibodies against h5n1 strains of influenza a virus

Publications (3)

Publication Number Publication Date
JP2010521147A JP2010521147A (ja) 2010-06-24
JP2010521147A5 JP2010521147A5 (enExample) 2011-05-06
JP5346820B2 true JP5346820B2 (ja) 2013-11-20

Family

ID=39760169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009553239A Expired - Fee Related JP5346820B2 (ja) 2007-03-13 2008-03-13 Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体

Country Status (5)

Country Link
US (2) US8124092B2 (enExample)
EP (1) EP2125886A2 (enExample)
JP (1) JP5346820B2 (enExample)
CN (1) CN102046654A (enExample)
WO (1) WO2008110937A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
EP1919504B1 (en) 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
JP5346820B2 (ja) * 2007-03-13 2013-11-20 エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
EP2178558B1 (en) 2007-07-11 2014-04-30 iBio, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
KR101732056B1 (ko) 2008-07-25 2017-05-02 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
GB0818356D0 (en) * 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
NZ592036A (en) 2008-10-22 2012-12-21 Inst Research In Biomedicine Methods for producing antibodies from plasma cells
MY183517A (en) * 2009-05-11 2021-02-24 Janssen Vaccines & Prevention Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
WO2011041391A1 (en) * 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
EP2603237A4 (en) * 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
CN102775469B (zh) * 2011-05-12 2018-02-09 厦门大学 甲型流感病毒核衣壳蛋白的抗原表位及其用途
PL2734545T3 (pl) 2011-07-18 2019-09-30 Institute For Research In Biomedicine Neutralizujące przeciwciała przeciwko wirusowi grypy A i ich zastosowania
JP2013087069A (ja) * 2011-10-17 2013-05-13 Toyobo Co Ltd Ｈ５亜型インフルエンザウイルスを特異的に認識するモノクローナル抗体
EP2793945B1 (en) 2011-12-05 2018-08-15 Trellis Bioscience, LLC Antibodies useful in passive influenza immunization
US9233152B2 (en) 2012-01-12 2016-01-12 Temasek Life Sciences Laboratory Limited Monoclonal antibodies targeting neutralizing epitopes on H5 influenza virus of clade 2.3
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
AU2013345072B2 (en) 2012-11-13 2017-12-07 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
IL241552B2 (en) 2013-03-14 2023-09-01 Contrafect Corp Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
CA2938726A1 (en) 2014-02-04 2015-08-13 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6614523B2 (ja) * 2014-03-28 2019-12-04 地方独立行政法人神奈川県立産業技術総合研究所 インフルエンザウイルスのｒｎａ依存性ｒｎａポリメラーゼのｐｂ２サブユニットに対するモノクローナル抗体
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
JP6837434B2 (ja) 2014-07-15 2021-03-03 メディミューン，エルエルシー 抗ｂ型インフルエンザ抗体の中和及びその使用
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
IL260413B2 (en) 2016-01-13 2024-01-01 Medimmune Llc Method of treating influenza a
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
PL238020B1 (pl) 2016-09-12 2021-06-28 Inst Biotechnologii I Antybiotykow Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne
SG10201913833PA (en) 2017-02-28 2020-03-30 Univ Pennsylvania Influenza vaccines based on aav vectors
LT3589730T (lt) 2017-02-28 2024-03-12 The Trustees Of The University Of Pennsylvania Adenoasocijuoto viruso (aav) monofiletinės grupės f vektorius, ir jo panaudojimo būdai
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
BR112019025243A2 (pt) 2017-06-02 2020-07-14 Pfizer Inc. anticorpos específicos para flt3 e usos dos mesmos
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20240288426A1 (en) * 2020-01-12 2024-08-29 Vanderbilt University Human antibodies to crimean congo hemorrhagic fever virus
WO2021202815A1 (en) * 2020-03-31 2021-10-07 Northeastern University Colorimetric and multiplexed isothermal rna-and antibody-based assay for sars-cov-2 and other viral diagnostics and cell analysis
CN114181302B (zh) * 2020-09-14 2023-03-24 东莞市朋志生物科技有限公司 针对甲型流感病毒的抗体、试剂盒和载体
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
CN1652815A (zh) * 2002-03-13 2005-08-10 麒麟麦酒株式会社 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法
JP5525688B2 (ja) 2005-08-19 2014-06-18 株式会社ビーエル インフルエンザウイルスｈ５亜型の免疫検出法
WO2007031550A2 (en) 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
GB0522460D0 (en) 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
RU2008134426A (ru) * 2006-01-26 2010-03-10 ЭйчИкс ДИАГНОСТИКС, ИНК. (US) Моноклональные антитела, связывающиеся с вирусом птичьего гриппа
JP2009537147A (ja) * 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008033105A1 (en) 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
BRPI0707728A2 (pt) 2006-09-15 2011-05-10 Fraunhofer Usa, Inc. anticorpos de gripe, composiÇço compreendendo os mesmos e seus usos em diagnàsticos e anÁlises clÍnicas
JP5346820B2 (ja) * 2007-03-13 2013-11-20 エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体

Also Published As

Publication number Publication date
US20100278834A1 (en) 2010-11-04
JP2010521147A (ja) 2010-06-24
US8124092B2 (en) 2012-02-28
EP2125886A2 (en) 2009-12-02
CN102046654A (zh) 2011-05-04
WO2008110937A3 (en) 2009-04-30
US20120114664A1 (en) 2012-05-10
WO2008110937A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
JP5346820B2 (ja) Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
JP6022515B2 (ja) 抗ａ型インフルエンザウイルス中和抗体およびその使用
JP6035332B2 (ja) Ａ型インフルエンザウイルス中和抗体及びその使用法
JP5814790B2 (ja) デングウイルス中和抗体およびその使用
CN110642944B (zh) 一种中和人感染h7n9甲型流感病毒的抗体及其用途
US10654915B2 (en) Antibodies useful in passive influenza immunization
EP3240570A1 (en) Bispecific antibodies against plasma kallikrein and factor xii
CN113480640B (zh) 中和抗流感结合分子及其用途
KR20230109785A (ko) 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2008125985A2 (en) Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
US20240092875A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
JP6101204B2 (ja) インフルエンザｈ５赤血球凝集素の主要中和エピトープに特異的なモノクローナル抗体
US20100061995A1 (en) Immunotherapy To Treat Or Prevent Viral Infection
JP2024536380A (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体及びその使用Ｉ
JP6622825B2 (ja) Ａ型インフルエンザウイルス中和抗体及びその使用法
US20220340644A1 (en) Influenza neutralizing antibodies and their uses
JP2017086068A (ja) Ａ型インフルエンザウイルス中和抗体及びその使用法
HK1260890B (zh) 登革热病毒中和抗体及其用途
HK1203410B (en) Antibodies useful in passive influenza immunization
HK1164898B (en) Dengue virus neutralizing antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130619

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130819

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees